Stoke Therapeutics, Inc. STOK NASDAQ

Stoke Therapeutics, Inc. (STOK) reported total assets of $418.43M and total liabilities of $65.98M for fiscal year 2025, resulting in total equity of $352.46M.

The company held $284.67M in cash and short-term investments. Total debt stood at $0.00, with net debt of $-84.22M. The Debt-to-Equity (D/E) ratio was 0 (conservative).

Current ratio is 5.28, indicating strong short-term liquidity. Interest coverage is -1.5x (weak).

Criteria supported by this page:

• HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (70/100) — Total assets $418.43M and equity $352.46M support the company's competitive scale
• VALUE (35/100) — Debt-to-Equity 0 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 53/100 with 3/7 criteria passed.

RLAY

Relay Therapeutics, Inc.

$14.75

-3.34%

HARP

Harpoon Therapeutics, Inc.

$23.01

+0.09%

ARVN

Arvinas, Inc.

$11.00

+3.97%

BDTX

Black Diamond Therapeutics, Inc.

$2.66

-2.21%

PLRX

Pliant Therapeutics, Inc.

$1.30

+0.38%

ADAP

Adaptimmune Therapeutics plc

$0.05

-3.00%

TCRR

TCR2 Therapeutics Inc.

$1.48

+0.00%

PASG

Passage Bio, Inc.

$10.86

+0.46%